TY  - JOUR
AU  - Fan, Zhiyao
AU  - Fan, Kun
AU  - Yang, Chao
AU  - Huang, Qiuyi
AU  - Gong, Yitao
AU  - Cheng, He
AU  - Jin, Kaizhou
AU  - Liu, Chen
AU  - Ni, Quanxing
AU  - Yu, Xianjun
AU  - Luo, Guopei
PY  - 2018
TI  - Critical role of  KRAS  mutation in pancreatic ductal adenocarcinoma
JF  - Translational Cancer Research; Vol 7, No 6 (December 30, 2018): Translational Cancer Research
Y2  - 2018
KW  - 
N2  - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers worldwide. Little progress has been made in recent years concerning its diagnosis and treatment. Genetic alterations can be found in approximately 97% of PDAC cases. Mutations in the  KRAS  gene, which encodes the  KRAS  protein that regulates cell proliferation, differentiation, and apoptosis via activation of downstream signal transduction pathways, occur most frequently.  KRAS  plays a pivotal role in modulating the tumor microenvironment in PDAC patients. Additionally,  KRAS  can regulate metabolic changes in PDAC cells in a variety of ways. Although previous studies have shown that  KRAS  mutation detection can be used for early diagnosis and to predict the prognosis of PDAC patients, and many paths have been proposed to suppress the effects of  KRAS , there is still no single pathway that leads to effective treatment of  KRAS -mutant PDAC. This review summarizes the role of  KRAS  mutation in PDAC and examines the association between  KRAS  mutation and clinical applications.
UR  - https://tcr.amegroups.org/article/view/25051